Literature DB >> 26522223

Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells.

Samir H Barghout1, Nubia Zepeda2, Zhihua Xu2, Helen Steed1, Cheng-Han Lee3, YangXin Fu4.   

Abstract

Ovarian cancer is the fifth leading cause of cancer-related mortalities in women. Epithelial ovarian cancer (EOC) represents approximately 90% of all ovarian malignancies. Most EOC patients are diagnosed at advanced stages and current chemotherapy regimens are ineffective against advanced EOC due to the development of chemoresistance. It is important to better understand the molecular mechanisms underlying acquired resistance to effectively manage this disease. In this study, we examined the expression of the Wnt/β-catenin signaling components in the paired cisplatin-sensitive (A2780s) and cisplatin-resistant (A2780cp) EOC cell lines. Our results showed that several negative regulators of Wnt signaling are downregulated, whereas a few Wnt ligands and known Wnt/β-catenin target genes are upregulated in A2780cp cells compared to A2780s cells, suggesting that Wnt/β-catenin signaling is more active in A2780cp cells. Further analysis revealed nuclear localization of β-catenin and higher β-catenin transcriptional activity in A2780cp cells compared to A2780s cells. Finally, we demonstrated that chemical inhibition of β-catenin transcriptional activity by its inhibitor CCT036477 sensitized A2780cp cells to carboplatin, supporting a role for β-catenin in carboplatin resistance in A2780cp cells. In conclusion, our data suggest that increased Wnt/β-catenin signaling activity contributes to carboplatin resistance in A2780cp cells.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carboplatin; Chemoresistance; Epithelial ovarian cancer; Wnt/β-catenin

Mesh:

Substances:

Year:  2015        PMID: 26522223     DOI: 10.1016/j.bbrc.2015.10.138

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

Review 1.  'Lnc'-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling.

Authors:  Mei S Ong; Wanpei Cai; Yi Yuan; Hin C Leong; Tuan Z Tan; Asad Mohammad; Ming L You; Frank Arfuso; Boon C Goh; Sudha Warrier; Gautam Sethi; Nicholas S Tolwinski; Peter E Lobie; Celestial T Yap; Shing C Hooi; Ruby Y Huang; Alan P Kumar
Journal:  Br J Pharmacol       Date:  2017-08-23       Impact factor: 8.739

Review 2.  Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways.

Authors:  Chuansheng Yang; Zhikai Mai; Can Liu; Shuanghong Yin; Yantao Cai; Chenglai Xia
Journal:  Molecules       Date:  2022-05-30       Impact factor: 4.927

3.  Long noncoding RNA UCA1 promotes carboplatin resistance in retinoblastoma cells by acting as a ceRNA of miR-206.

Authors:  Nanye Wang; Huimin Fan; Shuhua Fu; Shaojun Li; Bin Zhou; Qifang Jin; Zhipeng You
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

Review 4.  Prognostic utility of the ovarian cancer secretome: a systematic investigation.

Authors:  Pradnya R Kamble; Apoorva Pawar; Ananya A Breed; Grishma Kasle; Bhakti R Pathak
Journal:  Arch Gynecol Obstet       Date:  2022-01-27       Impact factor: 2.493

5.  Colon cancers carrying BRAF V600E and β-catenin T41A activating mutations are resistant to numerous common anticancer drugs.

Authors:  Guangzhong Xu; Kai Li; Nengwei Zhang; Bin Zhu; Guosheng Feng; Qing Fan
Journal:  Oncol Lett       Date:  2018-01-25       Impact factor: 2.967

Review 6.  B7-H3-targeted Radioimmunotherapy of Human Cancer.

Authors:  Benjamin B Kasten; Soldano Ferrone; Kurt R Zinn; Donald J Buchsbaum
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

7.  Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer.

Authors:  C E Henry; E Llamosas; A Djordjevic; N F Hacker; C E Ford
Journal:  Oncogenesis       Date:  2016-05-30       Impact factor: 7.485

8.  AKAP2 is upregulated in ovarian cancer, and promotes growth and migration of cancer cells.

Authors:  Xin Li; Changjun Wang; Gang Zhang; Ming Liang; Bin Zhang
Journal:  Mol Med Rep       Date:  2017-08-18       Impact factor: 2.952

Review 9.  LGR5 and LGR6 in stem cell biology and ovarian cancer.

Authors:  Adam J Schindler; Arisa Watanabe; Stephen B Howell
Journal:  Oncotarget       Date:  2017-08-11

10.  Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin.

Authors:  Jinli Zhang; Xifeng Xiong; Xing Hua; Wenjuan Cao; Shengnan Qin; Libing Dai; Peihong Liang; Huiling Zhang; Zhihe Liu
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.